Part, Chapter, Paragraph
1 -, 1 | more complex interpretative models than those currently available
2 I, 2. 7 | original drawings, plans and models documenting the production
3 I, 2. 10. 1| configuration into interactive models represent a particular challenge.~ ~
4 II, 5. 4. 2| HIS/HES evaluations and models, (01/09/2002).~ ~
5 II, 5. 5. 3| are using research-proven models. It is thus indispensable
6 II, 5. 5. 3| When multiple regression models were used to predict the
7 II, 5. 7. 1| infections. Interpretative models are being developed to frame
8 II, 5. 7. 6| long-term conditions. New models and new technologies (e.g.
9 II, 5. 8. 6| new and more responsive models of end-of-life care for
10 II, 5. 9. 4| potency in allergy animal models. Coarse (2.5-10 microm)
11 II, 5. 9. 4| the in vitro and in vivo models also showed a high degree
12 II, 5. 9. 4| in the different allergy models and between allergy and
13 II, 5. 9. 5| the effectiveness of these models of health care organization
14 II, 5. 11. 3| interpretation of mathematical models led the authors to conclude
15 II, 5. 12. 2| rates. Joinpoint regression models are performed using the “
16 II, 5. 14. 5| determinants, oral health delivery models and outcomes, and oral health
17 II, 7. 5 | prevent violence and injuries. Models are available from a number
18 II, 8. 1. 1| health policies. Until now, models of disability were typically
19 II, 8. 2. 1| intellectual disabilities. Models of good practice – at medical
20 II, 9. 3. 1| identified with the current models for depression (Branney &
21 II, 9. 3. 2| realities in the different models of care present in Europe.~ ~
22 II, 9. 5. 3| The absence of active role models may negatively influence
23 III, 10. 2. 1| conflicts and negative role models. A large number of studies
24 III, 10. 2. 5| even formation of permanent models of behaviour. A multitude
25 III, 10. 2. 5| neurotoxic in laboratory models. The toxic effects of such
26 III, 10. 3. 1| adequacy of the experimental models used and scarcity of data
27 III, 10. 3. 2| neurotoxic in laboratory models. The toxic effects of such
28 III, 10. 4. 2| Coordination of pesticide fate models and their USe) was established
29 III, 10. 4. 2| of the FOCUS groundwater models and their consistency in
30 III, 10. 4. 5| the use of pharmacokinetic models to assess the influence
31 IV, 11. 1. 5| organizational quality assessment models and clinical quality assessment
32 IV, 11. 1. 6| method, some alternative models have been devised. These
33 IV, 11. 5. 1| 10 pmp.~ ~Two different models are present in the EU:~ ~·
34 IV, 11. 5. 1| light of these two different models, the EU transplant geography
35 IV, 11. 5. 4| with some organisational models seem to be performing better
36 IV, 11. 6. 4| implementing probabilistic models for assessing performance
37 IV, 11. 6. 4| implementation of risk adjustment models is possible only for very
